Furthermore, clinical trials have demonstrated that HDACis strongly enhance therapy efficacy of EGFR inhibitors (Gerber et al. 2015) and platinum-based chemotherapy (Ramalingam et al. 2010) in NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.